VPValeriia Igorevna Pavlova

Valeriia Igorevna Pavlova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Valeriia Igorevna Pavlova has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Surgical treatment of primary multiple lung cancer in elderly and senile patients

    by E.B. Topolnitskiy, N.A. Shefer, V.I. Pavlova, A.G. Tkachev

    Objective. To evaluate early and long-term outcomes of surgical treatment for primary multiple lung cancer (PMLC) in elderly and senile patients and to characterize key aspects of perioperative management. Material and methods. A retrospective single-center study included 12 patients with verified PMLC who underwent surgery between 2010 and 2022. They were classified as elderly (60—75 years; n=9) or senile (76—85 years; n=3) according to the WHO classification. PMLC was confirmed using the Martini—Melamed criteria modified by Antakli and the Warren—Gates criteria. Patients underwent anatomical (lobectomy, bilobectomy, pneumonectomy) or sublobar (segmentectomy, wedge resection) lung resections, predominantly via video-assisted thoracic surgery. Postoperative complications were assessed using the Clavien—Dindo classification. Disease-free and overall survival after the second surgery were analyzed using the Kaplan—Meier method. Results. R0 resection was achieved in all patients. After surgery for the second primary lesion, postoperative complications occurred in 75% of cases. The most common events were prolonged air leak, residual pleural cavities, COPD exacerbation, and cardiac arrhythmias. No in-hospital mortality was observed. Mean postoperative hospital-stay was 8.4±2.1 days after the first surgery and 10.2±2.5 days after the second surgery. Following the second resection, 1-, 3- and 5-year disease-free survival rates were 93.9%, 84.4%, and 67.6%, respectively. Overall survival rates were 99.6%, 87.4%, and 76.6%, respectively. No significant differences in survival were found between lobectomy and sublobar resections. These findings should be interpreted as descriptive due to small sample size. Conclusion. In carefully selected elderly and senile patients, surgical treatment of PMLC provides acceptable rates of postoperative morbidity and 5-year survival comparable to published data. Anatomical resections are preferable in patients with sufficient functional reserves. In those with limited cardiopulmonary function, sublobar resections are an acceptable alternative.

  • Open Access

    Clinical and Diagnostic Features and Treatment Outcomes of Locally Advanced Medullary Thyroid Carcinoma in the Tyumen Region, Russia

    by M. I. Sokolova, V. I. Pavlova, E. A. Gaisina

    Introduction. Medullary thyroid carcinoma (MTC) is a rare and aggressive malignancy, accounting for 2–5% of all thyroid cancers. Aim. This study examined the epidemiological profile of MTC in the Tyumen Region (Russia) and evaluated the effectiveness and tolerability of multikinase inhibitors (MKIs) in MTC therapy. Materials and methods. The analysis included 69 patients with MTC treated between 2017 and 2025. Patient age ranged from 39 to 78 years (median 57). Sonographic characteristics of thyroid nodules were classified according to the EU-TIRADS. Cytological evaluation of fine-needle aspiration samples followed the Bethesda Thyroid Classification (2009, 2017, 2023). Survival outcomes were calculated using the Kaplan–Meier method. Serum calcitonin (CT) and carcinoembryonic antigen (CEA) levels were measured by electrochemiluminescence. RET mutation testing was performed on blood samples and, in one case, on surgical tissue. Results . Between 2017 and 2025, peak MTC incidence in the Tyumen Region occurred in 2021 and 2024, reaching 0.65 and 0.74 per 100,000 population, respectively. During cabozantinib therapy, mean survival was 19.30 months (95% CI 14.45–21.39), with a median of 17.01 months. For vandetanib in first-line therapy, mean survival was 18 months (95% CI 12.57–23.59), with a median of 14.00 months (95% CI 12.46–20.55). The objective response rate was 29.4% with vandetanib and 36.8% with cabozantinib. The most frequent adverse events were arterial hypertension with vandetanib, palmar-plantar erythrodysesthesia with cabozantinib, and toxic hepatitis with selpercatinib. Discussion. This retrospective analysis demonstrates the effectiveness and safety of MKIs in routine clinical practice. Cabozantinib showed superior survival outcomes and objective response rates compared to vandetanib. The observed adverse events were expected and manageable. The findings are consistent with published clinical evidence. Conclusion . Given the aggressive nature of MTC, continuous monitoring of disease progression is essential. In cases of progression, MKI therapy should be considered, with careful evaluation of potential toxicity in relation to individual treatment goals.

  • Using artificial intelligence tools to predict recurrence risk in pancreatic cancer. A systematic literature review and meta-analysis

    by M. Sh. Manukyan, V. I. Pavlova, R. Sh. Abdulaeva, T. G. Gevorkyan, S. S. Gordeev

    A systematic review and meta-analysis of 10 studies (2019–2024) evaluating the diagnostic accuracy of artificial intelligence (AI) algorithms for predicting pancreatic cancer (PCa) recurrence was conducted. The pooled sensitivity and specificity estimates were 0.77 [95 % CI: 0.58–0.95] and 0.79 [95 % CI: 0.57–1.00], respectively. Key limitations of the study included high heterogeneity (I² > 98 %), which could be related to the small number of included studies and insufficient standardization of the validation methods. Background: Artificial intelligence (AI) tools provide new possibilities in predicting the course of pancreatic cancer. Purpose: To conduct a meta-analysis of the diagnostic accuracy of AI algorithms (sensitivity and specificity) for predicting PCa recurrence and to compare the effectiveness of different types of algorithms. Methods. A systematic literature search was conducted in leading scientific databases, covering publications from 2019 to 2024. The review included studies that applied artificial intelligence tools to predict the risk of pancreatic cancer recurrence. The data search and analysis were conducted in three stages: a primary search of studies using keywords and inclusion criteria; screening of the titles and abstracts to select relevant studies; and a detailed assessment of the full texts of the selected articles. The data synthesis included an analysis of the performance of the AI models, the types of data used (clinical, genomic, radiological, etc.), and the validation and testing strategies for the proposed algorithms. A random-effects model was used for the sensitivity and specificity meta-analysis, with the calculation of pooled estimates, 95 % confidence intervals, and heterogeneity indices (I², τ²). A meta-regression was also performed to assess the impact of the algorithm type on sensitivity. Statistical analysis was carried out in R (metafor package) with forest plot visualization. Results: This systematic review included 10 studies, of which 5 were selected for the meta-analysis. The results demonstrate a pooled sensitivity of 0.77 [95 % CI: 0.58–0.95] and specificity of 0.79 [95 % CI: 0.57–1.00] for AI algorithms in predicting PCa recurrence. In the analysis of individual algorithm types, artificial neural networks (ANNs) showed a pooled sensitivity of 0.87 [0.73–1.01], while support vector machines (SVMs) had a negative impact on sensitivity (coefficient –0.45 [–0.69 to –0.21]). The meta-analysis revealed high heterogeneity of the studies (I² = 98.84 % for sensitivity and I² = 99.42 % for specificity), requiring cautious interpretation of the results. Conclusion: AI models are promising tools for predicting pancreatic cancer recurrence, but require data standardization and prospective validation in clinical practice.

  • Open Access

    Difficulties in differential diagnosis of intracranial solitary fibrous tumor: a clinical case

    by M. M. Akulov, R. S. Talybov, T. M. Kleschevnikova, V. I. Pavlova, T. N. Trofimova

    According to the 5th edition of the World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS), published in 2021, solitary fibrous tumor (SFT) has been established as a distinct nosological entity within the category of rare mesenchymal neoplasms, exhibiting a propensity for early recurrence and systemic dissemination.The limited prevalence of SFTs accounts for the scarcity of publications describing their specific neuroimaging patterns, while the clinicopathological features of this tumor have been well-characterized. The lack of robust diagnostic criteria poses significant challenges in differentiating SFTs from other intracranial neoplasms, which require fundamentally distinct therapeutic approaches. This report describes the clinical case of a 40-year-old male patient presenting with headache, systemic dizziness, recurrent syncopal episodes, and generalized tonic-clonic seizures over a two-month period. Brain MRI revealed an extra-axial mass in the left parasellar region, attached with its base to the dura mater, accompanied by perifocal edema, mass effect of the left temporal lobe, prominent vascularity, intense homogeneous contrast enhancement, and elevated perfusion values. The preoperative differential diagnosis included meningioma, schwannoma, dural metastatic lesion, chondrosarcoma, and MALT lymphoma. The «YinYang» sign emerged as the most significant diagnostic criterion, characterized by heterogeneous tumor signal intensity on T2- and T2-FLAIR sequences. The patient underwent microsurgical resection of the tumor. Histopathological examination confirmed the diagnosis of SFT. Thus, the use of a comprehensive multiparametric MRI protocol enables a high-probability preoperative suspicion of SFT, which is critical for surgical planning.

  • Intracranial solitary fibrous tumor: Difficulties in differential diagnosis of tumors and tumor-like lesions in a patient with HIV-infection: case report and literature review

    by Vladislav V. Spasennikov, Rustam S. Talybov, Tatiana M. Kleschevnikova, Valeria I. Pavlova, Tatiana N. Trofimova

    Based on current World Health Organization statistics, today there were an estimated 40 million people living with HIV. The specific epidemiological course of HIV infection is represented by a wide range of severe forms of diseases with a predominance of involvement of the central nervous system in the pathological process. Due to the variability of cerebral lesions, there are difficulties in identifying and diagnosing the pathological process, especially when it comes to a tumor process unrelated to HIV infection. A 40-year old man presented with left hemiparesis and headaches. He was diagnosed with human immunodeficiency virus (HIV) in 2020 and does not treat using antiretroviral (ARV) drugs. The CD4 + lymphocyte level was 180 cells/μl. The titers of antibodies to T.gondii were 1:400. Brain magnetic resonance imaging (MRI) revealed an intraaxial mass in the basal ganglia region on the right side, with ring-shaped contrast enhancement, restricted diffusion and extensive perifocal edema, small foci of hemorrhages and vascular shunts, and high perfusion levels. The patient underwent a stereotactic biopsy of the brain mass and postoperative pathological report confirmed the diagnosis of a primary neuroepithelial tumor: Glioblastoma, Not Otherwise Specified (NOS, WHO 2021). Correct and timely detection of the nature of brain lesion is necessary to select the correct treatment strategies and, as a result, reduce mortality. The use of multiparametric MRI protocol recommended to the differential diagnosis of brain lesions in patients with HIV infection.

  • Open Access

    Long-term outcomes in young patients with breast cancer. Multicenter, matched-cohort study

    by K. U. Memetov, A. A. Parokonnaya, E. S. Makarov, V. A. Suravatkin, A. A. Izmaylov, M. Y. Kuzmenko, V. I. Pavlova, R. A. Zukov, V. A. Ivanov, N. M. Fedorov, et al.

    Background. Despite existing clinical guidelines, representative data on breast cancer outcomes in patients aged 25 years and younger remain limited. Aim. To analyze long-term survival in this age group. Materials and methods. We conducted a retrospective, multicenter study that included patients treated between 2008 and 2020. From 552 tracked cases, 2 groups matched by disease stage and tumor molecular subtypes were formed using 1:2 pseudo-randomization: the study group (n = 63, age ≤ 25 years) and the control group (n = 126, age 25 years). The distribution of clinical stages was identical in both groups: in the study group, stage IA was observed in 11 patients (17.5 %), IIA in 18 (28.6 %), IIB in 13 (20.6 %), IIIA in 6 (9.5 %), IIIB in 7 (11.1 %), and IIIC in 8 (12.7 %); in the control group the corresponding numbers were 22, 36, 26, 12, 14, and 16 cases, respectively (the same proportions). Overall survival and recurrence-free survival (RFS) were assessed. Results. The analysis revealed a statistically significant decrease in RFS in the group of young patients. The median RFS was 73.9 months compared to 82.8 months in the control group, which is consistent with the survival analysis results (p = 0.027). The 5-year RFS was significantly lower – 55.7 % versus 77.1 %, and the 10-year RFS was 36.3 % versus 49.8 % (p = 0.027). Regarding overall survival, although the median and 5-year survival rates in the ≤ 25 years group were also lower (149.7 months and 79 % versus 157.3 months and 89 %, respectively), the difference did not reach statistical significance (p = 0.229). Conclusion. Patients with breast cancer aged ≤ 25 years have significantly lower recurrence-free survival, confirming the concept of more aggressive disease course in young age, likely associated with adverse biological features of the tumors. These findings underscore the need to identify modifiable prognostic factors and develop more effective treatment strategies for this patient category.

  • Open Access

    Artificial intelligence for predicting long-term outcomes in patients with colorectal cancer (a systematic review and meta-analysis)

    by R. Sh. Abdulaeva, V. I. Pavlova, T. G. Gevorkyan, Y. V. Belenkaya, M. Sh. Manukyan, S. S. Gordeev, Я. В. Беленькая

    AIM: to evaluate  the performance of artificial-intelligence algorithms in predicting long-term treatment outcomes in patients with colorectal cancer using clinical data alone to evaluate the performance of artificial-intelligence algorithms in predicting long-term treatment outcomes in patients with colorectal cancer (CRC) using clinical data alone. MATERIALS AND METHODS: a systematic search (2015–2024) was conducted in PubMed, Science Direct, MedRxiv, BioRxiv and Google Scholar. Original studies that applied machine-learning or deep-learning techniques exclusively to clinical variables for predicting CRC recurrence were included. Of 657106 records screened, 43 met the eligibility criteria; 12 were entered into a meta-analysis. Pooled area under the ROC curve (AUC), heterogeneity metrics (I², τ², Q-test), publication bias and sensitivity were assessed. Robustness was examined with a leave-one-out analysis. RESULTS: a systematic search (2015–2024) in PubMed, Science Direct, MedRxiv, BioRxiv and Google Scholar. Original studies that applied machine-learning or deep-learning techniques exclusively to clinical variables for predicting CRC recurrence were included. Of 657106 records screened, 43 met the eligibility criteria; 12 were entered into a meta-analysis. Pooled area under the ROC curve (AUC), heterogeneity metrics (I², τ², Q-test), publication bias and sensitivity were assessed. Robustness was examined with a leave-one-out analysis. CONCLUSION: AI models show promising accuracy in predicting colorectal cancer recurrence, supporting their potential utility in clinical decision-making. Nevertheless, further validation in large-scale, prospective studies is required before widespread clinical implementation.

  • Open Access

    Video-assisted and microsurgical resection with double contrast in oropharyngeal cancer

    by I. V. Reshetov, N. S. Sukortseva, I. V. Ponomarev, M. I. Sokolova, V. I. Pavlova

    Introduction. The incidence of oropharyngeal cancer is steadily increasing, mainly due to an increase in the number of cases of Hpv (human papillomavirus) infection. This is an important trend from a clinical point of view, since Hpv-positive oropharyngeal cancer is associated with a better prognosis and treatment results. Despite its visually accessible location, the diagnosis of oropharyngeal cancer can be challenging due to the complexity of its anatomical structure. The active development of minimally invasive transoral microsurgery, combined with fluorescent technologies, demonstrates the effectiveness of early diagnosis of oropharyngeal tumors.Aim. To improve the diagnosis of oropharyngeal tumors, introduction into clinical practice of transoral microsurgical resections with double contrasting.Materials and methods. In the clinic of plastic surgery of the first moscow medical university named after I.M. Sechenov, a method for early diagnosis of oropharyngeal cancer was developed. The method consisted in intraoperative sequential double contrasting of the mucous of the oropharynx with indocyanine green and methylene blue, followed by autofluorescent videopharyngoscopy, transoral microsurgical, video-assisted resection based on the use of an operating microscope and rigid end-point optics (endoscope). Eleven surgeries were performed successfully.Results. The postoperative period was smooth and uncomplicated in all patients. According to the data presented, local recurrence was confirmed in 18 % (2 patients out of 11) after special treatment for oropharyngeal cancer using our method.Conclusion. Modern treatment of cancer patients requires not only cure, but also careful monitoring of the disease. The use of transoral video-assisted and microsurgical resection based on double contrasting is an alternative method for early diagnosis of both primary oropharyngeal cancer and its recurrence.

  • Video-assisted lingual tonsillectomy in the identification of primary tumors in patients with CUP syndrome

    by M.I. Sokolova, V.I. Pavlova

    Objective. To analyze the role of video-assisted lingual tonsillectomy in the identification of latent oropharyngeal carcinoma in patients with CUP syndrome. Material and methods. The study is based on the results of diagnostic data from 68 patients with metastases of squamous cell carcinoma of unclear primary localization. The key criteria for inclusion in the study were the presence of metastases of squamous cell carcinoma in the lymph nodes of the neck, confirmed by morphological examination, the lack of data for the primary focus after the standard volume of clinical diagnostic studies, as well as the lack of data for metastatic lesion of lymph nodes of other localization. Taking into account the presence of increased expression of the p16 protein in metastatically altered lymph nodes of the neck and the lack of information about the primary tumor site after instrumental diagnosis and clinical examination, video-assisted lingual tonsillectomy in combination with cervical lymph node dissection was performed in 11 patients, which accounted for 16% of the total number. Results. Using the method of video-assisted lingual tonsillectomy, the primary tumor lesion localized in the root of the tongue was identified in 6 (55%) of 11 patients. The primary tumor in all operated patients was squamous cell carcinoma of varying degrees of differentiation. Conclusion. Analysis of p16 protein expression levels and performance of lingual tonsillectomy provide important diagnostic options in the detection of asymptomatic malignant tumors of the oropharynx. Identification of the primary tumor in patients with metastatic cervical lymph nodes of unknown primary localization is important in determining the extent of adjuvant therapy.

  • Open Access

    Comparative characteristics of the effectiveness of therapy with PARP inhibitor in patients with primary ovarian cancer in the Tyumen Region in the period from 2019 to 2023

    by M. Ya. Kuzmenko, V. V. Zhdanova, V. I. Pavlova, M. S. Shvedskiy

    Background. Malignant neoplasms of the ovaries are the fifth leading cause of death in women in the United States and the eighth in the world. Over the past ten years, both in Russia and in the Tyumen Region, there has been a gradual increase in the incidence of ovarian cancer: the average annual growth rate of standardized incidence rates from 2012 to 2022 in the Russian Federation was 0.03 %, and the overall increase was –2.52 %. Hereditary predisposition associated with the presence of a mutation in the BRCA1/2 genes plays a major role in the occurrence of this malignant disease.Aim. To evaluate the efficacy and tolerability of maintenance therapy with a PARP inhibitor in patients with high-grade serous and endometrioid ovarian cancer in the Tyumen Region from 2019 to 2023.Materials and methods. A retrospective statistical analysis of the overall incidence of ovarian malignancies, assessment of 5-year overall survival and progression-free survival in patients receiving a PARP inhibitor and previous platinumbased polychemotherapy was performed.Results. The total group of examined patients included 79 women, of whom PARP inhibitor as maintenance therapy for primary ovarian cancer was prescribed to 36 observed patients, a separate placebo group was allocated – 27 patients who did not receive targeted therapy after platinum-containing polychemotherapy regimens. In the course of the work, it was found that the use of PARP inhibitor demonstrates better results both in terms of 5-year overall survival (absolute gain was 11.6 %) and progression-free survival (absolute gain – 35.6 %).Conclusion. Regardless of the volume of cytoreduction and previous treatment regimens, disease progression against the background of taking a PARP inhibitor was observed significantly less frequently than in patients who did not receive targeted therapy: 33.3 % versus 58.6 %.